What is the primary objective of RoHS?

The primary objective of RoHS is to restrict hazardous substances in electrical and electronic equipment (EEE) to protect human health and the environment during waste management and recycling. Directive 2011/65/EU (RoHS 2), amended by (EU) 2015/863, limits ten substances—lead (Pb), mercury (Hg), cadmium (Cd), hexavalent chromium (Cr(VI)), PBB, PBDE, DEHP, BBP, DBP, DIBP—at 0.1% (1000 ppm) by weight in homogeneous materials (except 0.01% (100 ppm) for Cd), unless exempted. This enhances recyclability under an open-scope model for all EEE unless excluded.

Who is legally or professionally required to comply with RoHS?

Manufacturers, importers, distributors, and authorized representatives placing EEE on the EU market must comply with RoHS****. Responsibilities include ensuring homogeneous materials meet substance thresholds or exemptions (Annexes III/IV), preparing technical documentation per EN IEC 63000:2018, issuing EU Declarations of Conformity (DoC), and affixing CE marking where applicable. Scope covers 11 EEE categories unless excluded (e.g., large-scale fixed installations).

Does RoHS require an external audit or third-party certification?

No, RoHS does not require external audits or third-party certification. Compliance is self-assessed via technical files demonstrating conformity through supplier declarations, risk assessments, and testing (e.g., IEC 62321 methods). Authorities verify via market surveillance; retain files for 10 years.

How often should an assessment for RoHS be performed?

RoHS assessments must be performed upon product changes, supplier notifications, exemption expiries, and periodically via risk-based internal audits. Delegated directives amend Annexes frequently; re-assess high-risk materials (e.g., solders, plastics) annually, with tiered testing (XRF screening, ICP-MS/GC-MS confirmation) for ongoing verification.

What are the consequences of non-compliance with RoHS?

Non-compliance with RoHS results in decentralized Member State enforcement, including product withdrawal, recalls, sales bans, and fines. Penalties vary by jurisdiction (e.g., administrative fines, potential criminal liability); no unified EU schedule exists, but risks include market exclusion and CE marking invalidation.

Can RoHS be mapped to other international frameworks?

Yes, RoHS substance lists and thresholds align partially with frameworks like China RoHS 2 (core six substances, mandatory marking/E-PUP), but diverges in scope, exemptions, and disclosure. Mapping requires jurisdiction-specific adjustments (e.g., no EU-style exemptions in China RoHS 2).

What is the first step to begin implementing RoHS?

The first step to implement RoHS is scoping products to Annex I categories and exclusions, followed by homogeneous material-level BOM mapping. Identify high-risk materials, collect supplier declarations (IPC-1752 format), and build technical files per EN IEC 63000:2018.

What is the primary objective of FDA 21 CFR Part 11?

The primary objective of FDA 21 CFR Part 11 is to establish criteria under which the FDA considers electronic records and electronic signatures trustworthy, reliable, and equivalent to paper records and handwritten signatures (§11.1(a)). This equivalency enables electronic methods while ensuring authenticity, integrity, confidentiality (when appropriate), and non-repudiation through controls in Subparts B and C.

Who is legally or professionally required to comply with FDA 21 CFR Part 11?

FDA 21 CFR Part 11 applies to organizations using electronic records created, modified, maintained, archived, retrieved, or transmitted under predicate rules, or submitted electronically to FDA (§11.1(b)). It covers life sciences firms relying on electronic records in lieu of paper for regulated activities, including pharmaceuticals, devices, and biologics; paper printouts relied upon as official records generally fall outside scope per 2003 guidance.

Does FDA 21 CFR Part 11 require an external audit or third-party certification?

No, FDA 21 CFR Part 11 does not require external audits or third-party certification. Compliance is demonstrated through internal controls, validation, SOPs, and inspection readiness (§11.1(e)); FDA verifies during inspections, enforcing predicate rules and key provisions like access controls and signatures without mandating external validation.

How often should an assessment for FDA 21 CFR Part 11 be performed?

FDA 21 CFR Part 11 does not specify a fixed frequency for assessments; organizations must perform risk-based periodic reviews tied to change control, system lifecycle, and predicate rules. Per 2003 guidance and GAMP practices, reassess scope, validation, and controls during changes, annually for critical systems, or post-inspection to ensure ongoing fitness for use.

What are the consequences of non-compliance with FDA 21 CFR Part 11?

Non-compliance with FDA 21 CFR Part 11 can result in FDA enforcement actions including Form 483 observations, warning letters, product holds, recalls, and fines under predicate rules. The 2003 guidance notes continued enforcement of access controls, checks, training, signatures, and documentation; data integrity failures often lead to CGMP violations affecting product quality and patient safety.

Can FDA 21 CFR Part 11 be mapped to other international frameworks?

Yes, FDA 21 CFR Part 11 controls can be mapped to frameworks like EU Annex 11 for computerized systems, though Part 11 stands alone with its narrow scope and enforcement discretion per 2003 guidance. Common alignments include audit trails, access controls, and validation, enabling harmonized programs for global operations without cross-references required.

What is the first step to begin implementing FDA 21 CFR Part 11?

The first step to implement FDA 21 CFR Part 11 is to establish a formal applicability framework mapping predicate rules to records and assessing business reliance on electronic versions. Document scope decisions in SOPs per 2003 guidance, classifying systems as closed (§11.10) or open (§11.30) to prioritize controls like access limitation and signatures.

Standards Comparison

RoHS vs FDA 21 CFR Part 11

RoHS

Mandatory

2011

EU regulation restricting hazardous substances in EEE

FDA 21 CFR Part 11

Mandatory

1997

FDA regulation for trustworthy electronic records and signatures

Quick Verdict

RoHS restricts hazardous substances in EEE for EU market access, while FDA 21 CFR Part 11 ensures electronic records/signatures are trustworthy for US life sciences. Companies adopt RoHS for compliance/safety, Part 11 for digital validation and data integrity.

Hazardous Substances

RoHS

Directive 2011/65/EU Restriction of Hazardous Substances in EEE

Cost

€€€€

Complexity

High

Implementation Time

6-12 months

Key Features

Restricts 10 hazardous substances at 0.1% in homogeneous materials
Open-scope covers all EEE unless explicitly excluded
Time-limited exemptions via delegated directives
Requires technical file and EU Declaration of Conformity
Tiered verification using IEC 62321 testing methods

Electronic Records

FDA 21 CFR Part 11

21 CFR Part 11 Electronic Records; Electronic Signatures

Cost

€€€€

Complexity

High

Implementation Time

12-18 months

Key Features

Risk-based validation of computerized systems
Secure time-stamped audit trails for actions
Controls for closed and open systems
Linked electronic signatures with non-repudiation
Access and authority checks enforcement

Detailed Analysis

A comprehensive look at the specific requirements, scope, and impact of each standard.

RoHS Details

What It Is

Directive 2011/65/EU (RoHS 2) is an EU regulation restricting hazardous substances in electrical and electronic equipment (EEE). It aims to protect health and environment by limiting risks in waste management, using an open-scope approach covering all EEE unless excluded, with restrictions at the homogeneous material level.

Key Components

Restricts 10 substances (e.g., Pb, Cd, Hg, Cr(VI), phthalates) at 0.1% (Cd at 0.01%) by weight.
Annexes III/IV for time-limited exemptions.
Compliance via technical documentation, EU Declaration of Conformity (DoC), and CE marking where applicable.
Built on risk-based evidentiary model per EN IEC 63000; testing via IEC 62321.

Why Organizations Use It

Mandated for EU market access; prevents fines, recalls, bans. Enhances recyclability, supply chain integrity, ESG reporting. Builds stakeholder trust, levels playing field, drives substitution innovation.

Implementation Overview

Phased: scope analysis, BoM review, supplier declarations, tiered testing (XRF/ICP-MS), technical files. Applies to manufacturers/importers globally selling EEE; SMEs to enterprises. No central certification—retain files 10 years for surveillance; risk-based audits.

FDA 21 CFR Part 11 Details

What It Is

FDA 21 CFR Part 11 is a U.S. federal regulation defining criteria under which electronic records and electronic signatures are considered trustworthy, reliable, and equivalent to paper records and handwritten signatures. It targets FDA-regulated industries using electronic systems for predicate rule records, employing a risk-based approach narrowed by 2003 FDA guidance to focus on reliance and enforcement discretion.

Key Components

**Subparts A-CGeneral provisions, electronic records controls (§11.10 closed systems, §11.30 open systems), electronic signatures (§§11.50-11.300).
Core controls: validation, audit trails, access limits, operational/authority/device checks, signature linking/uniqueness.
Built on predicate rules; no formal certification, compliance via inspection readiness.

Why Organizations Use It

Mandatory for electronic GxP records; ensures data integrity, non-repudiation.
Mitigates enforcement risks (warnings, holds); enables paperless efficiency, faster inspections.
Builds stakeholder trust, supports digital transformation in pharma/devices.

Implementation Overview

Phased: scoping, risk assessment, CSV (IQ/OQ/PQ), SOPs/training, vendor governance.
Applies to life sciences; U.S.-centric; audited via FDA inspections.

Key Differences

Aspect	RoHS	FDA 21 CFR Part 11
Scope	Hazardous substances in EEE materials	Electronic records and signatures trustworthiness
Industry	EEE manufacturers, global with EU focus	Life sciences, pharma, devices, US-regulated
Nature	Mandatory EU product restriction directive	US FDA regulation with enforcement discretion
Testing	IEC 62321 material substance testing	Risk-based system validation IQ/OQ/PQ
Penalties	Decentralized MS fines, recalls, bans	Warning letters, holds, Form 483 observations

Scope

RoHS

Hazardous substances in EEE materials

FDA 21 CFR Part 11

Electronic records and signatures trustworthiness

Industry

RoHS

EEE manufacturers, global with EU focus

FDA 21 CFR Part 11

Life sciences, pharma, devices, US-regulated

Nature

RoHS

Mandatory EU product restriction directive

FDA 21 CFR Part 11

US FDA regulation with enforcement discretion

Testing

RoHS

IEC 62321 material substance testing

FDA 21 CFR Part 11

Risk-based system validation IQ/OQ/PQ

Penalties

RoHS

Decentralized MS fines, recalls, bans

FDA 21 CFR Part 11

Warning letters, holds, Form 483 observations

Frequently Asked Questions

Common questions about RoHS and FDA 21 CFR Part 11

RoHS FAQ

FDA 21 CFR Part 11 FAQ

You Might also be Interested in These Articles...

The Tool Landscape for Reaching and Maintaining ISO 27001 Compliance

Discover top ISO 27001 compliance tools, their pros/cons, implementation steps, costs, and benefits. Streamline your path to certification and ongoing complianc

CMMC Level 3 Implementation Guide: Integrating NIST SP 800-172 Enhanced Controls for APT Defense

Step-by-step CMMC Level 3 guide for DIB contractors. Implement 24 NIST SP 800-172 controls on Level 2. Prep for DIBCAC, C3PAO scoping & 180-day POA&Ms. Boost cy

Top 5 Unseen Complexities Modern Compliance Software Effortlessly Manages

Uncover top 5 unseen complexities modern compliance software manages effortlessly—from sensitive data mapping to real-time regulatory shifts. Automate audits, i

Run Maturity Assessments with GRADUM

Transform your compliance journey with our AI-powered assessment platform

Assess your organization's maturity across multiple standards and regulations including ISO 27001, DORA, NIS2, NIST, GDPR, and hundreds more. Get actionable insights and track your progress with collaborative, AI-powered evaluations.

100+ Standards & Regulations

AI-Powered Insights

Collaborative Assessments

Actionable Recommendations

Explore More Comparisons

See how RoHS and FDA 21 CFR Part 11 compare against other standards

Other RoHS Comparisons

Other FDA 21 CFR Part 11 Comparisons

What It Is

Key Components

Restricts 10 substances (e.g., Pb, Cd, Hg, Cr(VI), phthalates) at 0.1% (Cd at 0.01%) by weight.

Annexes III/IV for time-limited exemptions.

Compliance via technical documentation, EU Declaration of Conformity (DoC), and CE marking where applicable.

Built on risk-based evidentiary model per EN IEC 63000; testing via IEC 62321.

What It Is

Key Components

**Subparts A-CGeneral provisions, electronic records controls (§11.10 closed systems, §11.30 open systems), electronic signatures (§§11.50-11.300).

Core controls: validation, audit trails, access limits, operational/authority/device checks, signature linking/uniqueness.

Built on predicate rules; no formal certification, compliance via inspection readiness.

Aspect

RoHS

FDA 21 CFR Part 11

Scope

Hazardous substances in EEE materials

Electronic records and signatures trustworthiness

Industry

EEE manufacturers, global with EU focus

Life sciences, pharma, devices, US-regulated

Nature

Mandatory EU product restriction directive

US FDA regulation with enforcement discretion

Testing

IEC 62321 material substance testing

Risk-based system validation IQ/OQ/PQ

Penalties

Decentralized MS fines, recalls, bans

Warning letters, holds, Form 483 observations